Please assess the completion status of the following clinical trial:

Trial Title: Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between 18 and 70 years of age~* Planned allogeneic stem cell transplantation either from a related or an unrelated donor~* Written informed consent~Exclusion Criteria:~* Previous stem cell transplantation~* Use of antibody Campath (anti CD-52) or ATG during the conditioning~* In vitro T-cell depleted graft~* Known hypersensitivity to everolimus or other constituents of the study medication~* Symptomatic infectious disease~* Hepatic disease (ASAT \> 2 x ULN)~* Renal insufficiency (creatinine \> 2 x ULN)~* HIV infection~* Life expectancy \< 3 months~* Severe lung disease (FEV1 \< 50% of the normal value)~* Severe psychiatric disorder~* Subjects unlikely to comply with the requirements of the protocol~* Known or current alcohol, medication or drug abuse~* Pregnancy or lactation~* Women of child-bearing potential without reliable contraception unless they meet the following criteria: postmenopausal (12 months of natural amenorrhea);postoperation status (6 weeks after surgical bilateral oophorectomy with or without hysterectomy);use of highly effective birth control method (defined as one which results in a low failure rate i.e. less than 1% per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomized partner)~* Men that do not use one of the following methods for prevention of conception:sexual abstinence; condom; vasectomy~* Participation of the subject in another clinical trial within the last 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).